• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

BioCryst's persistence for patient insights leads to a bigger market for HAE drug Orladeyo

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 26, 2021 at 12:12: AM
via Sometimes finding out how patients really feel about treatment takes persistence. That's what BioCryst Pharmaceuticals learned when it started talking to patients about its new oral preventative treatment for hereditary angioedema.

article source
 




Top Bottom
Back
Quote